SPRINGER CAROLINE JOY,MARAIS RICHARD,GIROTTI ROMINA,NICULESCU-DUVAZ DAN,NICULESCU-DUVAZ ION,ZAMBON ALFONSO
申请号：
IN201627012740
公开号：
IN201627012740A
申请日:
2016.04.12
申请国别(地区):
IN
年份:
2016
代理人:
摘要：
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 1 (5 tert butyl 2 aryl pyrazol 3 yl) 3 [2 fluoro 4 [(3 oxo 4H pyrido[2 3 b]pyrazin 8 yl)oxy]phenyl]urea compounds (referred herein as TBAP compounds) that inter alia inhibit RAF (e.g. BRAF CRAF etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds and the use of such compounds and compositions both in vitro and in vivo to inhibit RAF (e.g. BRAF CRAF etc.) and to treat disorders including: proliferative disorders cancer (including e.g. malignant melanoma colorectal carcinoma pancreatic adenocarcinoma) inflammation immunological disorders viral infections fibrotic disorders disorders associated with a mutated form of RAF (e.g. BRAF CRAF etc.) disorders ameliorated by the inhibition of RAF (e.g. BRAF CRAF etc.) disorders ameliorated by the inhibition of mutant BRAF disorders ameliorated by the inhibition of BRAF and CRAF disorders associated with RAS mutations and/or MAPK pathway activation disorders ameliorated by the inhibition of SRC p38 FGFRA VEGFR 2 (KDR) and/or LCK etc.
